Read More Pharma Industry News Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered… byPallavi MadhirajuFebruary 28, 2025